AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 10, 2024
(Yulia Petrova/Getty Images) We all want to ‘age successfully’ with as few health issues as possible. A new study suggests getting more than seven hours of sleep a night could go a long way to achieving that goal.
Pharmaceutical Technology
NOVEMBER 10, 2024
Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in the field.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 10, 2024
The Department of Biotechnology (DBT) has invited researchers, scientists and clinicians to collaborate in multicentric projects to study consequences of viral infection including post Covid-19 impact on cardiovascular health, and prevention strategies, in order to gain insights into the therapeutic segment.
pharmaphorum
NOVEMBER 10, 2024
Recent funding rounds in the digital health arena feature digital pathology startup Aignostics, remote care specialists TCC, Yazen Health, and Nema Health, wearables developer Alimetry, and clinical trial automation startup Research Grid.Digital pathology specialist Aignostics, which develops artificial intelligence algorithms to glean information from medical images and combine it with epidemiological, clinical, and genomic data, has completed a $34 million Series B financing.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Law Blog
NOVEMBER 10, 2024
By Sarah Wicks & James E. Valentine — The U.S. Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.
pharmaphorum
NOVEMBER 10, 2024
Johnson & Johnson looks on course to make Darzalex the first approved drug therapy for smouldering multiple myeloma, after a phase 3 win
Expert insights. Personalized for you.
149 
Let's personalize your content